Skip to Content

Power Drugs

Problems with mitochondria – cells’ tiny energy-producing units – can cause illnesses as diverse as cancer and Parkinson’s disease. Volkmar Weissig, a pharmaceutical scientist at Northeastern University, says he’s devised the first drug delivery system that can shuttle a drug through a cell to target its mitochondria. Weissig coats drugs in a common antibacterial compound; the positively charged coating is attracted to the mitochondria, which are the most negatively charged parts of the cell. In a recent experiment with mice, Weissig found that tumors treated with the coated version of the cancer drug Taxol grew only half as much as those treated with the uncoated drug. Weissig says he could also use the approach to shuttle DNA to the mitochondria, a possible basis for gene therapy to correct mutations in mitochondrial DNA – which have been implicated in neurological diseases such as Parkinson’s and Alzheimer’s. A Boston startup company, MitoVec, plans to couple Weissig’s technology with several existing cancer drugs and begin testing it in humans in two to three years.

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.